Hydrogenology
Hydrogenology editorial study record

Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II)

Tamura T et al.; HYBRID II Study Group · EClinicalMedicine. 2023;58:101907.

HumanOther formsPublished 2023
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Multicenter randomized double-blind placebo-controlled trial

Research topic

Critical care and ischemia-reperfusion

Administration classification

Other forms

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Comatose adults aged 20–80 after cardiogenic out-of-hospital cardiac arrest

Sample

73 randomized: H₂ n=39; control n=34

Duration

18 hours after admission; outcomes assessed through 90 days

Intervention

2% H₂ added to supplementary oxygen through mechanical ventilation

Hydrogen form

H₂ added to ventilator gas with supplemental O₂ — not Brown’s gas.

H₂ specification

2% H₂ with clinically adjusted inspired O₂ reported in the protocol as 24–50%.

H₂ flow

Not reported — ventilator flow varied by patient, so no single absolute H₂ flow can be calculated.

O₂ delivered with H₂

O₂ was co-delivered at a clinically adjusted concentration; absolute O₂ flow in mL/min was not reported.

Comparator

Supplementary oxygen without H₂ using blinded gas cylinders

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Primary: CPC 1–2 at 90 days. Secondary: modified Rankin scale, survival and safety

Reported result

The primary outcome was not statistically significant: CPC 1–2 occurred in 56% with H₂ and 39% with control (p=0.15). Several secondary mRS and survival results favored H₂, but the trial was stopped early and was underpowered.

Results-extraction completeness

Full methods, outcomes, registration, funding and conflicts checked in the open-access full text; independent appraisal remains incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Stopped early because of pandemic enrollment restrictions, with 73 of 360 planned participants. The prespecified primary endpoint was null; positive secondary findings require cautious interpretation. Taiyo Nippon Sanso funded the trial.

Applies directly to

Selected comatose adults after cardiogenic out-of-hospital cardiac arrest receiving intensive post-arrest care.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 36969346 · DOI: 10.1016/j.eclinm.2023.101907

Publisher access

Open-access full text is available through PMC and the publisher.

Extraction basis

Open-access PMC and publisher full texts plus PubMed record.

Record revision

2026-08-10